Upstart Accuri Develops $25K Flow Cytometer; Price May Transform Market | GenomeWeb
NEW YORK (GenomeWeb News) — In a move that may transform the flow cytometry industry, start-up biotech Accuri Cytometers last week launched a flow cytometer that it believes is as good as or better than market-leading instruments with similar specifications, but costs about 75 percent less.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.